Patients who took Xarelto may get part of proposed $4.5–5.25 million settlement
A proposed Canada-wide class-action settlement for the blood thinner Xarelto would create a $4.5 to $5.25 million fund. Eligible claimants can review criteria and options on the class action site.
Copy link
By Torontoer Staff
A proposed Canada-wide settlement has been reached in class actions over the prescription blood thinner Xarelto, Merchant Law Group LLP announced Saturday. The actions were filed in Saskatchewan and Québec against Bayer Inc. and certain affiliates for alleged bleeding-related injuries linked to the drug.
If approved by the court, the settlement will create a fund worth between $4.5 million and $5.25 million to compensate eligible claimants, subject to the number of approved claims and court approval of fees and expenses.
Who is eligible
The Saskatchewan notice defines class members as Canadian residents, other than residents of Québec, who were prescribed and ingested Xarelto in Canada before Oct. 27, 2025. The notice also allows certain family members to make claims under provincial family compensation rules if they have a qualifying relationship to an affected person.
Separate class proceedings were filed in Québec. Residents of Québec should consult the Quebec class action site or legal notices for the specific eligibility criteria that apply in that province.
How much could claimants receive
The final amount available to individual claimants will depend on the approved settlement fund and the number of validated claims. The fund will cover compensation for specified bleeding events that are proven with supporting documentation, certain family compensation claims, provincial and territorial health-care costs paid on behalf of claimants, administration expenses, an honorarium for the representative plaintiff, and legal fees, disbursements and applicable taxes.
Bayer denies the allegations, and they have not been proven in court.
Merchant Law Group LLP settlement notice
What you should do next
Eligible Canadians do not need to take immediate action to participate if the settlement is approved. Those who prefer not to be part of the class must opt out by the deadline. Keep medical records, prescriptions and any documentation of bleeding events or health-care costs, as those will be required to support a claim.
- Review the official class action website for detailed eligibility rules and claim forms.
- Retain medical records, prescriptions and billing statements that document Xarelto use and any bleeding events.
- Decide whether to remain in the class or opt out. Opt-out deadline: March 10, 2026.
- If opting out, submit a completed opt-out form to MNP Ltd. at the address on the class action site by the deadline.
- Consider legal advice if you have questions about your eligibility or the impact of opting out.
Court approval and timeline
A hearing to request approval of the settlement agreement will be held in Regina on April 1 at 2 p.m. CST before the Saskatchewan court. If the court approves the agreement, claims processes and deadlines will be finalised and publicised on the class action website.
The law firm says the proposed settlement resolves the Saskatchewan and Québec class actions, but the defendants deny the allegations and liability has not been established in court. That is a standard part of many negotiated settlements.
If you were prescribed and used Xarelto in Canada and think you may be eligible, check the class action site for the full notice, claim instructions and contact information for the settlement administrator before the opt-out date.
Xareltoclass actionBayerprescription drugslegal
